Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Progenity stock

PROG
US74319F1075
A2P7FX

Price

0.69
Today +/-
+0
Today %
+0 %

Progenity stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Progenity stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Progenity stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Progenity stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Progenity's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Progenity Stock Price History

DateProgenity Price
7/8/20220.69 undefined
7/7/20220.69 undefined

Progenity Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Progenity, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Progenity from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Progenity’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Progenity. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Progenity’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Progenity’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Progenity’s growth potential.

Progenity Revenue, EBIT and net profit per share

DateProgenity RevenueProgenity EBITProgenity Net Income
2026e0 undefined-76.36 M undefined-90.15 M undefined
2025e0 undefined-83.04 M undefined-92.02 M undefined
2024e0 undefined-92.11 M undefined-95.82 M undefined
2023e0 undefined-83.23 M undefined-92.06 M undefined
2022e0 undefined-78.95 M undefined-92.06 M undefined
20211.25 M undefined-117.84 M undefined-247.41 M undefined
202074.3 M undefined-195.2 M undefined-192.5 M undefined
2019144 M undefined-140.1 M undefined-148 M undefined
2018128 M undefined-114.2 M undefined-129.1 M undefined

Progenity Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20182019202020212022e2023e2024e2025e2026e
12814474100000
-12.50-48.61-98.65-----
27.3429.86-25.68100.00-----
3543-19100000
-129-148-192-247-92-92-95-92-90
-14.7329.7328.65-62.75-3.26-3.16-2.17
45.245.227.596.1500000
---------
Details

Keystats

ⓘ

Revenue and Growth

The Progenity Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Progenity is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2018201920202021
       
69.23392.188.4
222.212.70.65
6.10.600
7.610.912.20
47.99.39.38
88.974.6126.398.43
15.315.917.84.01
0000
0000
5.74.83.80
6.26.26.26.07
200200200330
27.427.12810.41
116.3101.7154.3108.84
       
100200100150
124.2283.2453722.65
-142.5-348.5-541.3-788.69
0000
0000
-18.2-65.1-88.2-65.89
1115.817.48.71
6177.647.430.85
4.867.322.04
0000
1.210.60.01
78100.472.761.61
71.572.4161.7126.39
0000
3.812.9275.81
75.385.3188.7132.2
153.3185.7261.4193.81
135.1120.6173.2127.92
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Progenity provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Progenity's financial health and stability.

Assets

Progenity's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Progenity must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Progenity after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Progenity's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2018201920202021
-129-148-192-247
6651
6000
4632-51-25
5272104
7737
0000
-65-106-165-167
-4-3-40
5516-4-1
602000
0000
-1-198-1
-1079137172
-1273229165
--4.00-6.00-5.00
0000
-22-1559-3
0000
0000

Progenity stock margins

The Progenity margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Progenity. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Progenity.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Progenity's sales revenue. A higher gross margin percentage indicates that the Progenity retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Progenity's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Progenity's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Progenity's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Progenity. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Progenity's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Progenity Margin History

Progenity Gross marginProgenity Profit marginProgenity EBIT marginProgenity Profit margin
2026e100 %0 %0 %
2025e100 %0 %0 %
2024e100 %0 %0 %
2023e100 %0 %0 %
2022e100 %0 %0 %
2021100 %-9,427.2 %-19,792.8 %
2020-25.71 %-262.72 %-259.08 %
201930.21 %-97.29 %-102.78 %
201828.05 %-89.22 %-100.86 %

Progenity Stock Sales Revenue, EBIT, Earnings per Share

The Progenity earnings per share therefore indicates how much revenue Progenity has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Progenity earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Progenity's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Progenity’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Progenity's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Progenity Revenue, EBIT and net profit per share

DateProgenity Sales per ShareProgenity EBIT per shareProgenity Earnings per Share
2026e0 undefined0 undefined-0.49 undefined
2025e0 undefined0 undefined-0.5 undefined
2024e0 undefined0 undefined-0.52 undefined
2023e0 undefined0 undefined-0.5 undefined
2022e0 undefined0 undefined-0.5 undefined
20210.01 undefined-1.23 undefined-2.57 undefined
20202.7 undefined-7.1 undefined-7 undefined
20193.19 undefined-3.1 undefined-3.27 undefined
20182.83 undefined-2.53 undefined-2.86 undefined

Progenity business model

Progenity Inc. is an American company specializing in the development and marketing of diagnostic tests and genetic screening solutions. It was founded in 2012 and is headquartered in San Diego, California. Progenity is a leading provider of prenatal screening and diagnostic solutions. The company offers a wide range of tests that help expectant parents identify potential health risks for their unborn child. Progenity's prenatal screening palette includes tests for determining chromosomal abnormalities, genetic disorders, and other health risks. A major advantage of these tests is that they are non-invasive, meaning that no dangerous invasive procedures need to be performed. Another important division of Progenity focuses on gastrointestinal health, where the company offers various diagnostic tests to identify and treat gastrointestinal diseases early. This includes tests for detecting colon cancer as well as genetic tests that indicate an increased risk for familial colon cancer syndromes. Progenity also has a division that focuses on cardiovascular diseases. Here, they offer genetic tests, among other things, to determine the risk of heart disease. In addition, the company offers a wide range of diagnostic solutions for general health, such as tests for identifying infectious diseases like HIV or HPV. Progenity also offers its customers various screening and diagnostic tests tailored to specific target groups. This includes tests for women seeking fertility treatment, as well as tests aiming to identify specific hereditary diseases related to cancer or other conditions. To provide customers with the best possible solutions, Progenity utilizes state-of-the-art technologies and innovative methods. The company is a leader in the application of liquid biopsy tests, an innovative method for identifying cancer cells in the blood. For a long time, Progenity has worked closely with leading US health authorities and is accredited by CLIA, the Clinical Laboratory Improvement Amendments. This means that the company operates in accordance with established standards and best practices and can provide its customers with accurate and reliable diagnostic solutions. In recent years, Progenity has experienced an impressive growth rate and has become a recognized provider of diagnostic solutions with a wide range of tests covering various areas of health. The company is committed to providing customers with the best possible solutions to promote their health and well-being. Progenity is one of the most popular companies on Eulerpool.com.

Progenity SWOT Analysis

Strengths

Progenity Inc possesses several strengths that contribute to its competitive advantage in the market. These include:

  • Advanced technology and expertise in genetic testing and diagnostics.
  • Strong intellectual property portfolio, providing a barrier to entry for competitors.
  • Wide range of testing services, catering to various medical specialties.
  • Commitment to research and development, ensuring innovation and continuous improvement.
  • Strong relationships with healthcare providers and strategic partnerships, facilitating market reach.

Weaknesses

Despite its strengths, Progenity Inc also faces certain weaknesses that may impede its growth and market position:

  • Reliance on third-party payers for reimbursement, which can lead to pricing pressure.
  • Need for regulatory approvals for new tests, potentially causing delays in market entry.
  • High research and development costs, affecting profitability.
  • Intense competition from established players and emerging companies in the genetic testing industry.
  • Dependence on key personnel for strategic decision-making and operations.

Opportunities

Progenity Inc can leverage several opportunities to expand its business and enhance its market position:

  • Increasing demand for genetic testing due to advancements in precision medicine.
  • Growing awareness and acceptance of non-invasive prenatal testing.
  • Expansion into international markets to tap into a broader customer base.
  • Collaboration with pharmaceutical companies for companion diagnostics development.
  • Development of personalized medicine solutions, aligned with the trend of individualized healthcare.

Threats

Progenity Inc faces certain threats that could potentially hinder its growth and sustainability:

  • Stringent regulations and compliance requirements governing genetic testing.
  • Potential privacy and ethical concerns surrounding genetic data.
  • Price sensitivity of customers and payers, leading to downward pressure on testing fees.
  • Emergence of alternative technologies and methodologies for genetic testing.
  • Political and economic uncertainties impacting healthcare spending and reimbursement policies.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Progenity Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Progenity historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Progenity shares outstanding

The number of shares was Progenity in 2023 — This indicates how many shares 96.15 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Progenity earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Progenity's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Progenity’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Progenity's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Progenity.

Progenity Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals
SupplierCustomer0,930,70-0,25-0,65-0,320,78
Illumina Stock
Illumina
SupplierCustomer0,810,730,720,700,36-0,13
1

Most common questions regarding Progenity

What values and corporate philosophy does Progenity represent?

Progenity Inc represents a values-driven corporate philosophy focused on improving patient outcomes through innovative molecular testing solutions. The company is committed to enabling personalized medicine, providing physicians and patients with actionable insights to make informed healthcare decisions. Progenity's mission revolves around empowering individuals with the knowledge they need to lead healthier lives. With their comprehensive suite of molecular diagnostic tests, Progenity aims to address unmet medical needs in the fields of women's health, organ transplantation, and gastrointestinal disorders. By leveraging cutting-edge technology and a patient-centric approach, Progenity strives to deliver accurate, timely, and reliable results for healthcare providers and their patients.

In which countries and regions is Progenity primarily present?

Progenity Inc is primarily present in the United States.

What significant milestones has the company Progenity achieved?

Progenity Inc, a leading biotechnology company, has achieved several significant milestones. It successfully completed its initial public offering in June 2020, raising over $122 million in gross proceeds. The company has also expanded its portfolio of innovative molecular testing solutions, empowering healthcare providers and patients with essential genetic insights. Progenity Inc's groundbreaking research and development efforts have resulted in the launch of its flagship product, the Innatal® Prenatal Test, which aids in the detection of common fetal chromosomal disorders. Furthermore, the company has forged strategic partnerships with key industry players, solidifying its position as a pioneer in the field of genetic testing.

What is the history and background of the company Progenity?

Progenity Inc is a prominent company in the healthcare industry, focusing on personalized medicine and diagnostic solutions. Established in 2013, Progenity has quickly risen to prominence due to its innovative products and commitment to improving patient care. With a particular emphasis on genomic testing and precision medicine, Progenity offers a wide range of diagnostic tests, including prenatal and genetic screening. The company's comprehensive approach to healthcare has garnered recognition and partnerships with leading medical institutions. Progenity Inc continues to research, develop, and provide cutting-edge solutions that empower physicians and patients alike, promising a brighter future for personalized healthcare.

Who are the main competitors of Progenity in the market?

The main competitors of Progenity Inc in the market include companies such as Invitae Corporation, Guardant Health, Inc., and Natera, Inc.

In which industries is Progenity primarily active?

Progenity Inc is primarily active in the healthcare industry.

What is the business model of Progenity?

The business model of Progenity Inc revolves around providing innovative diagnostic solutions and precision medicine to improve patient care and outcomes. Progenity leverages its expertise in genomics, molecular biology, and bioinformatics to develop and commercialize specialized tests and diagnostic tools. The company offers a diverse range of services, including genetic testing, carrier screening, prenatal and reproductive health testing, and oncology testing. By combining advanced technologies and clinical expertise, Progenity aims to empower healthcare providers with actionable insights for personalized medicine, early disease detection, and tailored treatment plans. Progenity Inc is committed to revolutionizing patient care through its advanced diagnostic solutions and partnerships with healthcare professionals.

What is the P/E ratio of Progenity 2024?

The Progenity P/E ratio is -0.69.

What is the P/S ratio of Progenity 2024?

The Progenity P/S ratio is 0.

What is the Quality Investing of Progenity?

The Quality Investing for Progenity is 2/10.

What is the revenue of Progenity 2024?

The revenue cannot currently be calculated for Progenity.

How high is the profit of Progenity 2024?

The expected Progenity profit is -95.82 M USD.

What is the business model of Progenity

Progenity Inc is a leading company in prenatal diagnostics and personalized medicine. The company offers a wide range of products and services aimed at improving the health of mother and child during pregnancy and detecting genetic diseases or developmental disorders early on. Progenity Inc has several divisions, including the Progenity Testing Division, which specializes in non-invasive prenatal tests (NIPT), carrier screening, molecular testing, infertility diagnostics, and cancer diagnostics. Progenity's NIPT tests are highly accurate and provide reliable results regarding chromosomal abnormalities in the unborn child. These tests can be performed as early as the 10th week of pregnancy and only require a simple blood sample from the mother. Progenity's carrier screening tests identify genetic mutations that can be passed from parents to the unborn child and can lead to serious diseases. With this test, couples can determine if they are carriers of such mutations and assess the risk of their child developing these conditions. Progenity's molecular testing procedures allow doctors to identify the genetic causes of various diseases and plan more effective treatments. Progenity also offers comprehensive infertility diagnostics, allowing couples to identify the causes of their infertility and plan appropriate treatments. Progenity's Oncology Division offers a comprehensive range of genetic tests for cancer patients. These tests identify the genetic causes of specific types of cancer and enable the planning of individualized, personalized therapies. Progenity Inc also offers innovative solutions for reproductive health. The company has developed a unique platform called Eeva, which allows doctors to track the development of embryos in real time and select the best embryos for implantation. The Eeva platform improves the success rates of IVF treatments and reduces the likelihood of multiple pregnancies. Overall, Progenity Inc relies on innovative technologies and personalized medicine to improve the health of mother and child during pregnancy and facilitate the detection and treatment of genetic diseases. The company pursues a long-term strategy to continue its growth in this dynamic market and solidify its position as a leading company in prenatal diagnostics and personalized medicine.

What is the Progenity dividend?

Progenity pays a dividend of 0 USD distributed over payouts per year.

How often does Progenity pay dividends?

The dividend cannot currently be calculated for Progenity or the company does not pay out a dividend.

What is the Progenity ISIN?

The ISIN of Progenity is US74319F1075.

What is the Progenity WKN?

The WKN of Progenity is A2P7FX.

What is the Progenity ticker?

The ticker of Progenity is PROG.

How much dividend does Progenity pay?

Over the past 12 months, Progenity paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Progenity is expected to pay a dividend of 0 USD.

What is the dividend yield of Progenity?

The current dividend yield of Progenity is .

When does Progenity pay dividends?

Progenity pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Progenity?

Progenity paid dividends every year for the past 0 years.

What is the dividend of Progenity?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Progenity located?

Progenity is assigned to the 'Health' sector.

Wann musste ich die Aktien von Progenity kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Progenity from 12/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/12/2024.

When did Progenity pay the last dividend?

The last dividend was paid out on 12/12/2024.

What was the dividend of Progenity in the year 2023?

In the year 2023, Progenity distributed 0 USD as dividends.

In which currency does Progenity pay out the dividend?

The dividends of Progenity are distributed in USD.

All fundamentals about Progenity

Our stock analysis for Progenity Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Progenity Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.